Bilimsel Program
İstanbul MS Days
İstanbul MS Days
| 17:30 – 19:00 | PANEL – In Turkish Treatment options and barriers in treating the individual with MS in Turkiye |
||
| 19:00 – 19:15 | Rational Drug Use | ||
Dinner  |
|||
| 09:00 – 09:45 | Morning Satellite | ||
| 10:00 - 10:45 | Lecturing skills for young scientists Janet Hafler |
||
| 11:00 – 12:30 | TURKISH MS PANEL – In Turkish with lunch Building future-proof careers for young MS specialists in Türkiye |
||
| 13:00 – 14:00 | OFFICIAL OPENING | ||
| 13:00 – 13:10 | Welcome address 1: History of Istanbul MS Days Aksel Siva |
||
| 13:10 – 13:20 | Welcome address 2: From local roots to global aspirations – Dark Side of the Moon? Orhun H. Kantarci |
||
| 13:20 – 17:20 | SESSION-1 / I: From Posers’ Criteria to refined disease definitions of 2024 in inflammatory demyelinating diseases Discussants & Chairs: Jack Antel & Husnu Efendi & Axel Petzold |
||
| 13:20 – 13:40 | The clinician-scientist – finding the right questions for the right answers Brian G. Weinshenker |
||
| 13:40 – 14:00 | The scientist-clinician – using epidemiology evidence to develop individualized clinical practice Ellen Mowry |
||
| 14:00 – 14:20 | The clinician-clinician – Value of experience-based medicine in the extremes of disease Thomas Berger |
||
| 14:20 – 14:40 | The scientist-scientist – Developing models that reflect clinical questions accurately Katerina Akkasoglu |
||
| 14:40 – 15:00 | Discussion | ||
| 15:00 – 15:20 | Break  |
||
| 15:20 – 17:30 | SESSION-1 / II: Updates in Diagnostic Criteria and phenotyping definitions of inflammatory demyelinating diseases in 2024 and beyond Discussants & Chairs: Jack Antel & Husnu Efendi & Axel Petzold |
||
| 15:20 – 15:40 | The 2024 MS Diagnostic Criteria – What does it change? Xavier Montalban |
||
| 15:40 – 16:00 | Upcoming IPND-2025 Criteria – Will it add anything? Kazuo Fujihara |
||
| 16:20 – 17:00 | Do we need more detailed or more practical diagnostic criteria? TBA |
||
| 17:00 – 17:30 | Q&A, Discussion | ||
| 17:30 – 17:50 | Break |
||
| 17:50 – 20:00 | SESSION-2: Can we use science to fine tune health care delivery to the underserved? Discussants & Chairs: Mohamadali Sahraian & Magd Zakaria & TBA |
||
| 17:50 – 18:10 | The real-world needs of the underserved countries Riad Goudhier |
||
| 18:10 – 18:30 | Pitfalls in quantifying needs of the underserved and how to improve it TBA |
||
| 18:30 – 18:50 | Socialized vs. free-market economy for delivering healthcare to people in need TBA |
||
| 18:50 – 19:00 | Objective definitions of race & ethnicity – beyond the conventional Philip L. De Jager |
||
| 19:00 – 19:20 | Adjusting for geography in epidemiology studies in MS Alberto Ascherio |
||
| 19:20 – 19:50 | Q&A, Discussion | ||
| 20:20 | Dinner |
||
| 08:00 - 09:00 | Oral abstract presentations | ||
| 09:00 – 09:20 | Break |
||
| 09:20 – 12:00 | SESSION-3: Translating existing biomarkers to clinic? Discussants & Chairs: Naila Makhani & Turkish Co-Chair |
||
| 09:20 - 09:40 | Low field portable MRI - effective deployment to clinic – Serhat Okar |
||
| 09:40 - 10:00 | Real world use examples of CVS & PRLs Jiwon Oh |
||
| 10:00 - 10:20 | Utility of cervical cord MRI in MS diagnosis and prognosis Cristina Azevedo |
||
| 10:20 – 10:40 | Break |
||
| 10:40 – 11:00 | CSF biomarkers in MS Hayrettin Tumani |
||
| 11:00 – 11:20 | Integrating multiple biomarkers to diagnose, prognosticate and treat in the real world – The RIS experience Darin Okuda |
||
| 11:20 – 12:00 | Q&A, Discussion | ||
| 12:00 – 13:00 | Lunch Satellite |
||
| 13:00 – 15:20 | SESSION-4: Translating “futureomics” to clinic today? Chairs / Panelists: TBA & Turkish Co-Chair |
||
| 13:00 – 13:20 | Role of genomics in early diagnosis of MS Anat Achiron |
||
| 13:20 - 13:40 | Power of bioinformatics to solve complex proteomics of MS - Mika Gustaffson |
||
| 13:40 – 14:00 | Immunomics to practice in MS Amit Bar-Or |
||
| 14:00 – 14:20 | Break |
||
| 14:20 – 14:40 | Radiomics to delineate complex phenotypes in MS Korhan Büyüktürkoğlu |
||
| 14:40 - 15:00 | Pitfalls of integrating omics – human vs AI? Vilas Menon |
||
| 15:00 – 15:20 | Q & A Discussion | ||
| 15:20 - 15:40 | Break |
||
| 15:40 – 18:00 | SESSION-5: The MS continuum - polymorphic definition of relapses and progressive MS Discussants & Chairs: TBA & Turkish Co-Chair |
||
| 15:40 – 16:00 | The pathologist’s view of MS phenotypes Bruce Trapp |
||
| 16:00 – 16:20 | MRI markers of MS phenotypes Daniel Ontaneda |
||
| 16:20 - 16:40 | Non-MRI imaging biomarkers of MS phenotypes Peter A. Calabresi |
||
| 16:40 – 17:00 | Break |
||
| 17:00 – 17:20 | Relapses & Pseudorelpases – do we need updated definitions Eoin P. Flanagan |
||
| 17:20 - 17:40 | Towards practical composite metrics of preclinical and subclinical MS definitions Orhun Kantarcı |
||
| 17:40 – 18:00 | Q&A, Discussion | ||
| 18:00 - 18:20 | Break |
||
| 18:20 – 19:50 | SESSION-6: Using molecular imaging in MS – towards a practical goal Discussants & Chairs: Najib Kissani & Turkish Co-Chair & TBA |
||
| 18:20 - 18:40 | PET markers of myelin and oligodendrocytes Burcu Zeydan |
||
| 18:40 – 19:00 | PET markers of microglia function Laura Airas |
||
| 19:00 – 19:20 | PET Astrocyte imaging markers TBA |
||
| 19:20 - 19:50 | Q&A, Discussion | ||
| 20:15 | Dinner |
||
| 08:00 - 09:00 | Oral presentations | ||
| 09:00 – 09:15 | Break |
||
| 09:15 – 12:00 | SESSION-7: The treatment of MS today and tomorrow Chairs / Panelists: Rana Karabudak & Dimitrios Karussis & Samia Khoury |
||
| 09:15 - 09:35 | Treating MS in the young age Silvia Tenembaum |
||
| 09:35 – 09:55 | How to treat MS in the old age Nikolaos Grigoriadis |
||
| 09:55 - 10:15 | Hormones and adjunct therapies in MS TBA |
||
| 10:15 - 10:30 | Break |
||
| 10:30 – 10:50 | New developments in B cell depletion David Hafler |
||
| 10:50 – 11:10 | Microglia targets – BTK inhibitors and beyond Daniel Reich |
||
| 11:10– 11:30 | How to apply advanced imaging modalities for future clinical trials Nicola De Stefano |
||
| 11:30 – 12:00 | Q&A, Discussion | ||
| 12:00 – 13:00 | Lunch Satellite |
||
| 13:00 – 15:30 | SESSION-8: Rethinking trial design in multiple sclerosis Chairs / Panelists: Hans-Peter Hartung & Turkish Co-Chair & Turkish Co-Chair |
||
| 13:00 – 13:20 | Sex and ethnicity impact on clinical trial results TBA |
||
| 13:20 - 13:40 | Impact of limited recovery from relapses in practice and in clinical trials Claire Riley |
||
| 13:40 – 14:00 | Designing future proof clinical trials with multiple variables a priori Maria Pia Sormani |
||
| 14:00 – 14:20 | Break |
||
| 14:20 – 14:40 | Missing spinal cord data and beyond in clinical trials – mismatch with clinical practice Matilde Inglese |
||
| 14:40 - 15:00 | Using AI to model for prognostic variables in clinical trials Cristina Granziera |
||
| 15:00 – 15:30 | Q & A, Discussion | ||
| 15:30 - 15:45 | Break |
||
| 15:45 – 18:30 | SESSION-9: Treating the whole spectrum Discusssants & Chairs: Jacqueline Palace & Paulus Rommer & Turkish Co-Chair |
||
| 15:45 – 16:05 | Sensitivity and specificity of laboratory biomarkers in MS, NMO and MOG Orhan Aktas |
||
| 16:05 – 16:25 | The challenges of treating overlapping autoimmune diseases with MS Aksel Siva |
||
| 16:25 – 16:45 | The new NMO era of treating NMO – What should be the first line? Friedemann Paul |
||
| 16:45 – 17:05 | Treating MOGAD – where are we now? TBA |
||
| 17:05 – 17:20 | Break |
||
| 17:20 – 17:40 | mRNA vaccines for MS and autoimmune diseases TBA |
||
| 17:40 – 18:00 | Where is the next innovation in treating inflammatory-demyelinating disease spectrum Heinz Wiendl |
||
| 18:00 – 18:30 | Q&A, Discussion | ||
| 18:30 - 18:45 | Break |
||
| 18:45 – 19.15 | Istanbul MS Days Lecture Chairs: Rana Karabudak & Husnu Efendi & Orhun Kantarcı & Aksel Siva |
||
| Potential for overcoming regulatory limitations on off-label use of immunomodulation through large consensus statements TBA |
|||
| 19:15 – 20:15 | Summary and review of the meeting by the young Turkish MS Experts | ||
| 20:30 | Faculty - Farewell Dinner |
||